Influx Healthtech IPO: Influx Healthtech launched its initial public offering (IPO) for public subscription on June 18, with the issue scheduled to remain open until June 20. The health and wellness-focused company is looking to raise ₹55.63 crore through this SME IPO. The price band for the offer has been fixed between ₹91 and ₹96 per equity share.

The issue was subscribed 25.41 times at the end of the second day. The public issue subscribed 36.02 times in the retail category, 1.69 times in QIB, and 32.28 times in the NII category as of 6 pm on Saturday.

Influx Healthtech GMP today The company’s shares in the grey market traded at ₹38. This indicates an estimated listing price of ₹134, a premium of 39 percent from IPO price of ₹96.

It is important to understand that the grey market premium (GMP) merely reflects investor sentiment in the unofficial market and may fluctuate significantly. It should not be viewed as a guaranteed indicator of the stock’s future performance post listing.

About the IPO Influx Healthtech IPO is a combination of fresh issue of 46.94 lakh shares aggregating to ₹45.07 crores and offer for sale of 11.00 lakh shares aggregating to ₹10.56 crores. Retail investors were required to apply for a minimum of 1,200 shares, translating to a base investment of approximately ₹1.15 lakh.

The funds raised through the IPO will mainly be utilised to establish two new manufacturing facilities focused on the nutraceutical and veterinary segments, with an allocation of ₹34.19 crore. A portion of the proceeds will also go towards acquiring machinery and meeting general corporate expenses.

The allotment status for the Influx Healthtech IPO is likely to be finalised on June 23. Equity shares are expected to be credited to the Demat accounts of successful applicants by June 24, while refunds for unsuccessful bidders will also be initiated on the same day.

Shares of Influx Healthtech are set to debut on NSE SME on June 25.

According to IPO analyst Dilip Davda of Chittorgarh.com, Influx Healthtech Ltd (IHL), which functions as a contract development and manufacturing organisation (CDMO) in the healthcare sector with three operational units, has shown consistent growth in revenue over the reporting periods. However, he flagged concerns over the sharp rise in profits in FY24 and FY25, calling it potentially unsustainable given the intense competition and fragmentation in the industry. He noted that the IPO appears fairly valued based on recent financials and suggested that only well-informed or cash-rich investors consider a moderate investment with a medium-term horizon. Davda assigned the issue a ‘may apply’ rating.

Influx Healthtech’s IPO is being managed by Rarever Financial Advisors Pvt. Ltd., which is leading the issue as the book-running manager. Maashitla Securities Pvt. Ltd. has been designated as the registrar for the offering, while R.K. Stock Holding Pvt. Ltd. will serve as the market maker.

About the Company Influx Healthtech Ltd operates within the health and wellness sector, offering an extensive suite of services that include product development and third-party manufacturing. The company’s offerings span across nutraceuticals, cosmetics, ayurvedic formulations, and veterinary feed supplements.

The company runs its manufacturing operations from facilities located in Thane, which produce a wide variety of products such as tablets, gummies, jellies, skincare items, and ayurvedic solutions.

In terms of financial performance, Influx Healthtech reported a revenue of ₹104.99 crore for FY25, with a net profit of ₹13.37 crore.

Influx Healthtech Limited is gearing up to launch its Rs 58.57 crore IPO, opening for subscription from 18th June to 20th June.

The issue comprises a fresh issue of Rs 48 crore and an offer-for-sale worth Rs 10.56 crore. The shares for the same will be listed on NSE SME.

Retail investors need to invest at least Rs 1,15,200, while HNIs must apply for a minimum of Rs 2,30,400 (2,400 shares or 2 lots).

Maashitla Securities is acting as the registrar to the issue, with Rarever Financial Advisors as the lead manager. The market maker for this issue is R.K. Stock Holding.

As of 4:25 PM on 16th June, 2025, the Grey Market Premium (GMP) for Influx Healthtech IPO stands at Rs 35. With an IPO price band of Rs 96, the expected listing price is Rs 131, indicating listing gains of 36.46%.

Date GMP Expected Listing Price Last Updated 16-06-2025 Rs 35 Rs 131 4:25 PM 15-06-2025 Rs 35 Rs 131 11:30 PM 14-06-2025 Rs 31 Rs 127 11:30 PM 13-06-2025 Rs 24 Rs 120 11:30 PM 12-06-2025 Rs 20 Rs 116 11:30 PM

Everything You Need to Know About the Influx Healthtech IPO

Face Value Rs 10 per Share Lot Size 1,200 Shares Issue Price Band Rs 91 to Rs 96 per Share Listing At NSE SME Total Issue Size 61,00,800 Shares (aggregating up to Rs 58.57 Cr) Fresh Issue 50,00,400 Shares (aggregating up to Rs 48 Cr) Offer-for-Sale 11,00,400 Shares (aggregating up to Rs 10.56 Cr) DRHP Click Here RHP Click Here

Opening – Closing Dates 18th June – 20th June Cut-off Time for UPI Mandate Approval 5 PM on 20th June IPO Allotment 23rd June Amount Refund 24th June Credit of Shares 24th June Listing Date 25th June

Lot Size Details for Influx Healthtech IPO

Application Lots Shares Amount Retail (Min) 1 1,200 Rs 1,15,200 Retail (Max) 1 1,200 Rs 1,15,200 HNI (Min) 2 2,400 Rs 2,30,400

Influx Healthtech Company Details

Founded in September 2020, Influx Healthtech Limited is a contract manufacturer focused on the healthcare space. It operates as a CDMO (Contract Development and Manufacturing Organization), offering development, manufacturing, and regulatory support to clients across industries.

Key Highlights:

Operates three facilities in Thane, Maharashtra, with areas of 9,676 sq ft, 13,000 sq ft, and 14,000 sq ft.

Specialises in manufacturing products like: Tablets, capsules, powders Liquid orals, softgels, lozenges, jellies, gummies Oral dispersible films (ODFs), effervescent tablets, liquid-fill capsules Candies, gym/sports supplements Skin care, body care, hair and beard care products Face masks, soaps, ayurvedic/herbal items Veterinary feed supplements and homecare products

Influx Healthtech supports nutraceutical and cosmetic companies by handling the entire backend — from product development to manufacturing — so clients can focus on marketing and sales.

As of 11th June, 2025, the company has 163 full-time employees.

Influx Healthtech Company Finances

Period Ended 31st Mar, 2025 31st Mar, 2024 Assets (in Rs Cr.) 70.30 41.10 Revenue (in Rs Cr.) 104.99 100.10 Profit After Tax (in Rs Cr.) 13.37 11.22

Financial Performance:

Revenue: The company generated Rs 104.99 crore in revenue during the period ended on 31st March, 2025.

Financial Position:

Assets: The company’s total assets amounted to Rs 70.30 crore as of March 2025.

Profit After Tax (PAT): The company reported a PAT of Rs 13.37 crore for the financial year ending March 2025.

Influx Healthtech IPO FAQs

What is the price band set for the Influx Healthtech IPO?

The issue price band for the Influx Healthtech IPO is Rs 91 to Rs 96 per share.

What is the total issue size of the Influx Healthtech IPO offering?

The total issue size of the IPO is Rs 58.57 crore.

What is the lot size for the Influx Healthtech IPO?

Each lot consists of 1,200 shares, with a minimum investment of Rs 1,15,200.

What are the allotment and listing dates for the Influx Healthtech IPO?

The allotment is set for 23rd June, and the listing is scheduled for 25th June.

Curious About A Stock? Ask the Analyst.

Ready to invest like a pro? Unicorn Signals app equips you with 100+ Free tools and knowledge you need to succeed. Download the Unicorn Signals app and gain access to daily stock lists and insightful market analysis and much more!

The Influx Healthtech IPO is a book-building issue worth Rs 55.63 crore. It comprises a fresh issue of 46.94 lakh shares, worth Rs 45.07 crore, and an offer-for-sale of 11 lakh shares, amounting to Rs 10.56 crore.

The price band for the IPO has been fixed between Rs 91 and Rs 96 per share.

Retail investors can invest in the IPO by bidding for a single lot size of 1200 shares, requiring an investment of Rs 1,15,200.

Of the 43,64,400 shares on offer

11,59,200 (26.56%) are allocated to Qualified Institutional investors

8,70,000 (19.93%) are allocated to Non-Institutional investors

20,29,200 (46.49%) are allocated to Retail investors

The Influx Healthtech IPO will remain open for subscription from till June 20. The allotment of shares is scheduled to be finalised on June 23. Successful bidders will receive the shares in their Demat accounts on June 24. Refunds for non-allottees will also be processed on the same day.

Influx Healthtech’s IPO listing is scheduled for June 25. Shares of Influx Healthtech Ltd. will be listed on the NSE SME platform.

Rarever Financial Advisors Pvt. is the book-running lead manager of the Influx Healthtech IPO. Maashitla Securities Pvt. is the registrar and RK Stock Holding Pvt. is the market maker for the issue.

The dam finally seems to be breaking in the digital health world.

There was a surge of digital health companies going public in 2020 and 2021, but many of those that made the leap have faced significant challenges. Accolade, which went public in 2020, was recently taken private by Transcarent after losing key customers. Amwell, another 2020 IPO, has seen its stock value decline sharply as telehealth has become commoditized. Perhaps in response to these difficulties, only a handful of digital health companies have ventured into the public markets in the last couple of years.

Until now.

In just the last month, musculoskeletal company Hinge Health and chronic condition company Omada Health have gone public. And although it’s still early days, many experts are calling their debuts a success so far. Hinge Health went public on May 22 with an offer price of $32 a share, while Omada Health went public last week with an offer price of $19 a share, according to Yahoo Finance. Hinge’s market capitalization was about $3 billion and it raised $437 million, and Omada’s was about $1.1 billion and raised $150 million. As of June 12, Hinge is trading above its offer price, while Omada is trading a little below.

“I think what most differentiates them relative to a lot of the others that you saw, particularly in 2021 when there was this SPAC mania, was both are the kind of leading company in the space in which they compete,” said John Beadle, co-founder and managing partner of Aegis Ventures, in an interview. “They both have a path to profitability. In Hinge’s case, they’re already profitable and [Omada has] a clear path to get there within a reasonable amount of time. Both have a lot of operational maturity and really experienced management teams, and both have been around quite a long time and have a long operating history.”

Another healthcare investor said there was a “collective sigh of relief” that both companies traded above their offer price. Hinge’s stock closed at $37.56 on its debut, 17% up from its offer price of $32. Omada’s stock closed at $23, a 21% increase from its offer price of $19.

“I think there was some anxiety that [there’d be] a broken IPO, that after the offering price, the stocks traded down, and both of them traded up nicely,” said Michael Greeley, cofounder and general partner of Flare Capital Partners, in an interview.

Sponsored Post Navina’s AI Copilot Eases the Value-Based Burden, Study Shows A new independent study from Phyx Primary Care’s Innovation Lab points to measurable improvements in physician burnout, documentation efficiency, and key VBC metrics among primary care practices.

Greeley did flag at the time of the interview on Tuesday that Omada’s stock was down 14%, which is not of concern just yet, but is worth noting.

While many have called Hinge and Omada’s early days on the public markets a success, Seth Joseph, founder and managing director of consulting firm Summit Health Advisors, said that it’s in the eye of the beholder.

“Hinge’s early investors did well, but others have noted that at $3 billion, its current market capitalization is about half the $6 billion valuation in 2021,” he said. “Omada raised quite a bit less and was never as high flying, so it’s easier to point to as a success for all involved.”

What to watch for

It’s important to note that going public isn’t the final chapter for Hinge and Omada.

“Reaching this milestone is in itself significant and an affirmation of both businesses,” said Bill Evans, founder and general partner of Rock Health Capital, a seed fund. “At the same time, an IPO isn’t a destination; it’s a waypoint. Expectations only go up from here.” Rock Health is an investor in Omada, but not Hinge.

The most “anxious period” will be the next six months, according to Greeley. The existing venture capital investors are locked up for six months, meaning they’re not able to trade their shares and get a return on their investment.

“It’s just a very nerve wracking window that early investors now have to kind of weather,” he said. “And so if the stocks continue to trade up, then actually it’s to their benefit that they weren’t able to sell, because they’re getting even more of a gain. If the stocks start to trade down, there’s nothing you can do. You’re just watching.”

This lockup period is true of all IPOs, unless the bankers decide to release early investors early based on their assessment of market conditions, Greeley added.

He also said that there will likely be a series of announcements and partnership news coming from these companies to reinforce that they’re valuable.

Others are taking a slightly longer view.

Beadle believes that the real sign of success for Hinge and Omada will be how they’re performing a year from now. Every company faces tough earnings at some point. The real test of a public company is how it handles that first wave of bad news, he said.

“I think it’s very hard for companies that are not hugely free cash flow generative to be public because the market can sour on your name fairly quickly, often for insignificant reasons. … The only certainty I think about running businesses is there’s always going to be bad news in one form or another. So I think what will be most telling is, as we look back a year from now, as both companies need to deal with their first bad news events, how do they manage that?” he noted.

What will also be interesting is if they can sustainably grow while they’re public. There will be a lot of M&A opportunities for both companies. For Omada, there could also be an opportunity to expand if they decide to shift to prescribing weight loss drugs, Beadle said. They’re currently focused on providing behavior change programs for people taking GLP-1s without actually distributing the drug. This would be the “fastest vector of growth if they decided to take it,” according to Beadle.

Joseph is less confident in Omada’s ability to grow.

“Hinge is sitting on $470 million in cash (versus just $60 million for Omada), so it seems we might expect more acquisitions for Hinge. How does Omada reach more meaningful scale?” he said.

While both Omada and Hinge offer joint and muscle health support, it’s important to note that they primarily operate in distinct spaces. Omada is best known for diabetes care.

While many digital health companies have struggled in the public market in the past, Evans noted that it’s important to think about the companies’ differences, both from each other and other listed companies.

“Though they’re both in healthcare and both ‘use tech,’ it’s easy to overlook how different they really are and a bit tricky to fit them into existing categories,” Evans said. “As category leaders, the problems they solve, their business models, and their history all make them a bit different. Public market investors are still learning about both companies, and it may take time for consensus to emerge.”

Will more companies follow suit?

Omada and Hinge’s IPOs are a “sign of thawing markets” and a positive for other later-stage startups, Joseph said. There are several companies he anticipates to go public soon, including Maven Clinic, Included Health, Sword Health and Zocdoc.

Beadle agreed that these IPOs will likely spur additional companies to go public, and listed Innovaccer and Commure as ones to watch.

Hinge and Omada’s IPOs are beneficial for early-stage companies as well.

“It’s also encouraging for founders just starting out and the investors looking to fund very early stage companies, so they can point to recent successful exits,” Joseph said.

Photo: jxfzsy, Getty Images

Listen to the article 4 min This audio is auto-generated. Please let us know if you have feedback

Dive Brief:

Omada Health went public Friday, marking the second recent digital health IPO after a dry spell for the sector.

The digital chronic condition management company opened at $23 per share, a 21% bump over its public offering price of $19 per share.

Omada’s debut comes on the heels of virtual musculoskeletal company Hinge Health’s IPO last month. “I think it is definitely a promising bellwether for the industry,” John Beadle, co-founder and managing partner of Aegis Ventures, told Healthcare Dive.

Dive Insight:

Omada, which was founded in 2011 and has raised hundreds of millions of dollars in venture capital funding, offers digital management programs for conditions like diabetes, obesity and hypertension. Care teams also work with patients to build treatment plans and equip users with connected devices like blood pressure cuffs or digital scales.

The company filed to go public in May. Now, Omada is trading on Nasdaq under the ticker symbol “OMDA,” having raised $150 million in its IPO. The firm’s public offering price of $19 was at the midpoint of the expected range it released Thursday.

Omada’s IPO comes as the digital health sector has seen few public offerings in recent years. A surge of companies notched public exits in 2021, but the number has declined significantly in recent years.

Many digital health companies that went public during the boom — particularly ones that used mergers with special purpose acquisition companies — performed poorly, and may have been better off as strategic M&A targets, Beadle said.

However, the industry seemed poised for more companies to make the leap this year, and their performance could push others to follow in their footsteps, experts told Healthcare Dive late last year.

Now, two digital health companies have gone public in recent weeks. Hinge debuted on the New York Stock Exchange in May, opening 23% above its public offering price. Still, the sector isn’t seeing a flood of digital health companies moving to go public like in 2021, Beadle said.

“I don’t think there’s that many companies that are ready and have the operational maturity, growth trajectory [and] outcomes that Hinge and Omada do,” he said. “But I think both companies were exceptionally well prepared to do well when they went public.”

Though Hinge had given back most of its early post-IPO gains by the time of Omada’s pricing, its performance still provided a “good tailwind” for the chronic conditions management firm, Edward Best, co-chair of the capital markets practice at Willkie Farr & Gallagher, said via email.

Still, larger macroeconomic conditions will also impact whether more digital health companies decide to make the leap to the public markets. Some technology companies decided to delay their IPOs this spring after tariffs announced by President Donald Trump roiled the markets.

Stability is key to the IPO market, as investors will likely choose safer investments during periods of volatility, Best said. Companies need to think about their own operations and readiness to go public as well as broader conditions.

“The IPO market has periods when the window is more open than others. A company that is ready and wants or needs to go public when the window is open should certainly take a long hard look within,” he said. “Waiting too long could mean missing the window.”